Kirby Institute
- Country
- 🇦🇺Australia
- Ownership
- Private
- Established
- 1986-01-01
- Employees
- 101
- Market Cap
- -
- Website
- https://kirby.unsw.edu.au
Pravastatin for Hyperlipidaemia in HIV.
- Conditions
- HIV InfectionsLipid MetabolismGlucose MetabolismMetabolic AbnormalityLipodystrophyCardiovascular Disease
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2006-06-09
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00227500
- Locations
- 🇦🇺
St. Vincents Hospital, Sydney, New South Wales, Australia
A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 Study
- Conditions
- HIV Infections
- Interventions
- Drug: saquinavir 500 formulationDrug: cross-over arm
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2009-06-26
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00192608
- Locations
- 🇦🇺
St Vincents Hospital, Sydney, New South Wales, Australia
HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)
- Conditions
- HIV-Associated Lipodystrophy SyndromeCardiovascular Disease
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-04-12
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 80
- Registration Number
- NCT00192660
- Locations
- 🇦🇺
St. Vincent's Hospital, Sydney, New South Wales, Australia
A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-25
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 357
- Registration Number
- NCT00192634
- Locations
- 🇦🇺
QLD Health - AIDS Medical Unit, Brisbane, Queensland, Australia
🇦🇺John Hunter Hospital, Newcastle, New South Wales, Australia
🇦🇺The Centre Clinic, Melbourne, Victoria, Australia
Tenofovir in HIV/HBV Coinfection
- Conditions
- Hepatitis B CoinfectionHIV Infection
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2015-04-01
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 36
- Registration Number
- NCT00192595
- Locations
- 🇦🇺
St. Vincent's Hospital, Darlinghurst, New South Wales, Australia
🇹🇭Thai Red Cross AIDS Research Centre, Bangkok, Thailand
🇦🇺The Alfred Hospital, Melbourne, Victoria, Australia
Australian Trial in Acute Hepatitis C
- Conditions
- Hepatitis C
- Interventions
- Drug: Pegylated Interferon alfa 2aDrug: Ribavirin (HIV conifected patients only)
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 167
- Registration Number
- NCT00192569
- Locations
- 🇦🇺
The Alfred Hospital, Melbourne, Victoria, Australia
🇦🇺Western Hospital, Footscray, Victoria, Australia
🇦🇺Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects
- Conditions
- LipodystrophyCardiovascular DiseaseGlucose Metabolism DisordersMetabolic DiseasesHIV InfectionsDyslipidemias
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-04-12
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 50
- Registration Number
- NCT00192621
- Locations
- 🇦🇺
St Vincents Hospital, Sydney, New South Wales, Australia
Toxicity Substudy of Evaluation of Subcutaneous Proleukin in a Randomised International Trial (ESPRIT): TOXIL-2 Substudy
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2012-04-12
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 28
- Registration Number
- NCT00147355
- Locations
- 🇦🇷
FUNCEI, Buenos Aires, Argentina
🇦🇷Hospital Prof. Alejandro Posadas, Buenos Aires, Argentina
🇦🇺Nambour Hospital, Nambour, Queensland, Australia
Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy
- Conditions
- HIV-Associated LipodystrophyHIV Infections
- Interventions
- Device: poly-L-lactic acid
- First Posted Date
- 2005-08-03
- Last Posted Date
- 2009-04-02
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 100
- Registration Number
- NCT00126308
- Locations
- 🇦🇺
Dr Doong's Surgery, Burwood, New South Wales, Australia
🇦🇺Gladstone Road Medical Centre, Brisbane, Queensland, Australia
🇦🇺Gold Coast Sexual Health Clinic, Gold Coast, Queensland, Australia